Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI alert system aims to slash deadly hospital blood clots

NCT ID NCT06939803

First seen Jan 08, 2026 · Last updated Jun 23, 2026 · Updated 32 times

Summary

Hospital-acquired blood clots are a leading cause of death in U.S. hospitals. This study tests an AI tool called VTE-AI that automatically identifies patients at high risk for clots and alerts doctors to consider prevention. About 2,200 adults admitted to four hospitals will be randomly assigned to either the AI tool or the standard manual risk assessment. The goal is to see if the AI tool reduces the number of blood clots that form during hospital stays.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VENOTHROMBOEMBOLISM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    RECRUITING

    Nashville, Tennessee, 37203, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AI-driven clinical decision support tool (VTE-AI)

What this could lead to

If successful, this AI tool could become a standard way to prevent deadly blood clots in hospitals, saving thousands of lives and reducing long-term complications.

What could go wrong

The trial is still recruiting and results are not yet available. The AI tool may not reduce clots more than current methods, and there is a small risk of increased bleeding from prevention medications.

Conditions

The condition(s) this trial relates to.

venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.